IHS Chemical Week

Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients

Pharma/fine chemicals roundup—20 June 2013

7:32 AM MDT | June 20, 2013 | Deepti Ramesh

Ash Stevens to manufacture ponatinib API Ash Stevens (Riverview, MI), a provider of global contract pharmaceutical drug substance development and active pharmaceutical ingredient (API) manufacturing services, says that the US FDA has approved Ash Stevens’ manufacturing facility at Riverview, for the manufacture of the API in Ariad Pharmaceuticals' recently approved oncology drug Iclusig -ponatinib. The drug was granted accelerated approval in December 2012 by the FDA for the treatment of adult patients with chronic, accelerated or blast phase chronic...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week member yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine in print or digital format
  • Critical daily news and analysis on chemweek.com
  • Free mobile edition 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now

100% Satisfaction Guarantee
If at any time you are not completely satisfied with IHS Chemical Week, simply notify us and we'll refund the balance of your paid subscription - no problem.

Learn more about group subscriptions and site licenses.


contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa